You are not currently logged in.
Access JSTOR through your library or other institution:
If You Use a Screen ReaderThis content is available through Read Online (Free) program, which relies on page scans. Since scans are not currently available to screen readers, please contact JSTOR User Support for access. We'll provide a PDF copy for your screen reader.
Progress in Low-LET Heavy Particle Therapy: Intracranial and Paracranial Tumors and Uveal Melanomas
Mary Austin-Seymour, John E. Munzenrider, Michael Goitein, Richard Gentry, Evangelos Gragoudas, Andreas M. Koehler, Patricia McNulty, Estelle Osborne, David K. Ryugo, Joanna Seddon, Marcia Urie, Lynn Verhey and Herman D. Suit
Radiation Research Supplement
Vol. 8, Heavy Charged Particles in Research and Medicine. Proceedings of a Symposium Held at the Lawrence Berkeley Laboratory, University of California, Berkeley, California, May 1-3, 1985 (Nov., 1985), pp. S219-S226
Published by: Radiation Research Society
Stable URL: http://www.jstor.org/stable/3583531
Page Count: 8
Since scans are not currently available to screen readers, please contact JSTOR User Support for access. We'll provide a PDF copy for your screen reader.
Preview not available
The Harvard Cyclotron Laboratory in collaboration with the Department of Radiation Medicine of the Massachusetts General Hospital and the Retina Service of the Massachusetts Eye and Ear Infirmary provides low-LET heavy particle therapy with 160 MeV protons. The improved dose distribution of protons results from their physical characteristics. A total of 965 patients have been treated as of December 31, 1984. Dose is expressed in units of cobalt gray equivalent (CGE) which is the dose in Gy multiplied by the RBE (1.1) for modulated protons relative to 60 Co radiation. Sixty-seven patients with chordomas or low-grade chondrosarcomas of the base of skull or cervical spine have received proton treatment. Forty-three of these patients have been followed for at least 8 months with a median follow-up of 27 months. The median dose is 69 CGE. The 3-year actuarial local control rate is 89%. Seven patients with gliomas, eight with craniopharyngiomas, and six with meningiomas have also received proton radiation treatments. A total of 615 patients with uveal melanomas have received a median dose of 70 CGE in five fractions. Tumor regression has been seen in 94% with 66% having vision of 20/100 or better.
Radiation Research Supplement © 1985 Radiation Research Society